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Abstract 
Background: Insulin growth factor 1 (IGF‑1) has multiple effects on metabolism. Much evidence suggests that the 
deficiency of this hormone increases insulin resistance, impairs lipid metabolism, augments oxidative damage and 
deregulates the neuro‑hormonal axis. An inverse relationship between IGF‑1 levels and the prevalence of Metabolic 
Syndrome (MetS) with its cardiovascular complications has been identified. However, the underlying mechanisms 
linking IGF‑1 and MetS are still poorly understood. In order to elucidate such mechanisms, the aim of this work was to 
study, in mice with partial IGF‑1 deficiency, liver expression of genes involved in glucose and lipid metabolism as well 
as serum levels of glucose, triglycerides and cholesterol, as well as liver malondialdehyde (MDA) levels, as a marker for 
oxidative damage.
Methods: Three experimental groups were studied in parallel: Controls (CO), wild type mice (igf‑1+/+); untreated 
heterozygous mice (Hz, igf‑1+/−) and Hz (igf‑1+/−) mice treated with low doses of IGF‑1 for 10 days (Hz + IGF‑1).
Results: A reduction of IGF‑1 serum levels in the Hz group was found, which was normalized by IGF‑1 therapy. Serum 
levels of glucose, triglycerides and cholesterol were significantly increased in the untreated Hz group as compared 
to both controls and Hz + IGF‑1 groups. The expression of genes involved in gluconeogenesis, glycogenolysis, lipid 
synthesis and transport, and catabolism were altered in untreated Hz animals and the expression of most of them was 
normalized by IGF‑1 therapy; MDA was also significantly increased in the Hz untreated group.
Conclusions: The mere partial IGF‑1 deficiency is responsible for the reduction in the expression of genes involved 
in glucose and lipid metabolism, resulting in dyslipidemia and hyperglycemia. Such genetic alterations may seriously 
contribute to the establishment of MetS.
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Background
Insulin-like growth factor 1 (IGF-1) is an anabolic hor-
mone mainly produced in the liver by growth hormone 
(GH) endocrine stimulus [1]. IGF-1 possesses multiple 
effects on metabolism [2].
Interestingly, GH and insulin act in symphony with 
IGF-1 to produce a harmonious and coordinated 
response [3–5]. There is a yearly increasing number of 
studies suggesting the role of IGF-1 in metabolic coordi-
nation [2]. Accumulated evidence has proven an IGF-1 
implication in lipid and glucose metabolism [5, 6].
Recent data support that IGF-1 deficiency increases 
insulin resistance, impairs lipid metabolism, promotes 
oxidative damage and deregulates the neuro-hormonal 
axis [7–9]. IGF-1 circulating levels decrease with aging, 
and such a decrease is associated with insulin resistance 
and dyslipidemia. Interestingly, IGF-1 replacement ther-
apy improved the overall homeostasis [7]. On the other 
hand, an inverse relationship between IGF-1 circulat-
ing levels and incidence of metabolic syndrome (MetS) 
with liver steatosis, insulin resistance, hyperlipidemia 
and visceral obesity has been identified [10–13]. In addi-
tion, cardiovascular complications of MetS have been 
also reported [14].The majority of the studies have found 
that patients with MetS suffer more from cardiovascular 
disease (CVD) and an increased predisposition towards 
developing it [15–18].
Moreover, the MetS is also a good predictor for the 
development of type 2 Diabetes (T2D) [19–21]. Insulin 
resistance, hyperinsulinemia, dyslipidemia and obesity 
precede the progression to T2D [22] and the presence of 
MetS increases up to five fold the risk for T2D as com-
pared to controls [21, 22]. The risk is increased up to six- 
to sevenfold, if insulin resistance is also present [23].
On the other hand, MetS is strongly related with insu-
lin resistance and obesity, as well as non-alcoholic fatty 
liver disease (NAFLD), polycystic ovarian syndrome, 
hypogonadism and microvascular disease among others 
[23–25].
In this physiopathological context the underly-
ing mechanism between the IGF-1 deficiency and the 
establishment of MetS is poorly understood. In order 
to gain more insight into these mechanisms, an experi-
mental model of partial IGF-1 deficiency was used [26]. 
The experimental protocol included three groups of 
adult mice (28 ± 6 weeks old): untreated, heterozygotes 
(igf1+/−) mice with partial IGF-1 deficiency; heterozy-
gotes (igf1+/−) mice treated with IGF-1; and wild type 
(igf1+/+) mice that served as controls.
The specific aim of this work was to investigate whether 
the mere IGF-1 deficiency is able to alter the expres-
sion of genes involved in glucose and lipid metabolic 
pathways. Thus, liver gene expression studies carried 
out by microarray technique followed by RT-qPCR con-
firmation; serum levels of IGF-1, glucose, cholesterol 
and triglycerides were determined as well as MDA in 




The experimental model was established and character-
ized as previously reported [26]. Briefly, IGF-1 heterozy-
gous mice were obtained by cross-breeding transgenic 
mice, line 129SV and Igf1tm1Arge [27].
Animal genotype determination was performed by 
PCR analysis (Applied Biosystems, 2720 Thermal Cycler, 
Spain). DNA was extracted from a piece of tail and spe-
cific primers were used to identify both igf-1 and neo 
genes (Extract-N-Amp TM Tissue PCR KIT Sigma, 
USA).
Animals were housed in cages in a room with a 12-h 
light/dark cycle, constant humidity (50–55  %) and tem-
perature (20–22  °C). Food (Teklad Global 18  % protein 
rodent diet, Harlan Laboratories, Spain) and water were 
given ad libitum. All experimental procedures were per-
formed in compliance with The Guiding Principles for 
Research Involving Animals and approved by the Bioeth-
ical Committee from our institution.
Three groups of male mice 28  ±  6  weeks old were 
included in the experimental protocol: Controls wild type 
mice (CO, igf-1+/+, n = 10); untreated heterozygotes mice 
(Hz, igf-1+/−, n = 10) and heterozygous animals subcuta-
neously treated with IGF-1 (2 µg/100 g body weight/day) 
for 10 days (Hz + IGF-1, igf-1+/−, n = 10). Both the CO 
and Hz groups received vehicle (succinate buffer). IGF-1 
was provided by Chiron Corporation, USA.
On the 11th day mice were weighed, blood was 
obtained from submandibular vein and thereafter ani-
mals were sacrificed by cervical dislocation. The liver was 
carefully dissected out, weighed (Denver Instrument, 
Germany) and divided in 2 sections: left lobe was stored 
in RNAlater (Qiagen-Izasa, Spain) at −80 °C for microar-
ray and PCR RNA analyses, and right lobe for histology 
and MDA assessment.
Serum and liver analysis
Serum levels of IGF-1 were determined by ELISA in a 
Varioskan spectrophotometer (Thermo Scientific, Fin-
land), following specific commercial assay protocol 
instructions (Chiron Corporation, USA).
The serum concentrations of glucose, triglycerides 
and cholesterol were determined by routine laboratory 
methods by a COBAS INTEGRA 400 Plus auto analyzer 
(Roche-Hitachi, Germany), Calibration Reagents (Roche) 
and Cassettes of the same brand.
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Malondialdehyde levels
Malondialdehyde (MDA) was used as an index of lipid 
peroxidation and was measured after heating samples 
at 45  °C for 60  min in acid medium. It was quantitated 
by a colorimetric assay using LPO-586 (Bioxytech; OXIS 
International Inc., Portland, OR, USA), which, after 
reacting with MDA, generates a stable chromophore 
that can be measured at 586 nm (Hitachi U2000 Spectro; 
Boehringer Mannheim). Determinations were performed 
in homogenates of liver tissue in Tris–HCl solution (1 g 




Liver mRNA was isolated from animals belonging to the 
three experimental groups in accordance with the proto-
col outlined in RNAqueousH-Micro Kit (Ambion, USA). 
Technical procedures for microarray analysis, includ-
ing quality control of mRNA, labeling, hybridization 
and scanning of the arrays were performed according to 
standard operating procedures for Affymetrix protocols 
(GeneChipH Expression Analysis Manual, Affymetrix, 
USA). The mRNAs were profiled using Affymetrix HT 
MG-430. The array signals were normalized using Robust 
Multichip Averages [28] and batch-effects of the three 
replicates were corrected using ComBat [29]. Differen-
tially expressed genes between Hz + IGF-1 and CO sam-
ples were selected using FDR-corrected p value of 0.01 (p 
value of < 0.05).
Total RNA extraction, reverse transcription and quantitative 
real time polymerase chain reactions (RT‑qPCR)
Hepatic lobules were cryopreserved in RNAlater (Qia-
gen-Izasa, Spain). The day performing PCR determina-
tions hepatic samples were homogenized with TRIzol 
reagent (Invitrogen, UK) by Tissue Lyser LT (Qiagen-
Izasa, Spain) and RNA was extracted and purified using 
the (Qiagen), RNeasy Mini Kit including digestion with 
RNase-free DNase, following the manufacturer’s instruc-
tions. RNA quality was checked by the A260:A280 ratio 
and with Bioanalyzer 2100 (Agilent Technologies Inc., 
USA). Purified RNA was then converted to cDNA by 
using the RNA-to-DNA EcoDryTM Premix (Clonetech 
Labs, USA) for qPCR assays. Quantitative real time PCR 
assays were performed in a 3100 Avant Genetic Analyzer 
(Applied Biosystems Hispania, Spain). The thermal pro-
file consisted of an initial 5 min melting step at 95 °C fol-
lowed by 40 cycles at 95 °C for 10 s and 60 °C for 60 s.
Specific Taqman® probes for the selected genes 
(Acaa1b, Acat1, Acsl1, Acot9, Fabp1, Fabp5, Hmgcs1, Lpl, 
Lrp1, Pcsk9, Ankra2, Hmgcr, G6pc, Pck1, Pdk4, Acly, Igf1, 
Igfbp1, and Igfbp3) were supplied by Applied Biosytems.
The relative mRNA levels of the genes of interest 
were normalized to Tbp expression using the simpli-
fied comparative threshold cycle delta, cycle threshold 
(CT) method [2−(ΔCT gene of interest  −  ΔCT actin)] [30]. Tbp 
was selected fot endogenous control after carefully ana-
lyzing 12 genes (Actb, B2m, Gapdh, Gusb, Hsp90ab1, 
Ldha, Pgk1, Ppih, Sdha, Tbp, Tfrc, and Ubc), which are 
widely used as housekeeping genes. Only 5 out of these 
12 did not vary their expression when comparing Hz 
with Controls. We assayed those 5 genes and selected the 
one, which showed more stable and reproducible values, 
which was Tbp, a very stable gene coding for a transcrip-
tion factor that binds the TATA box.
Statistical analysis
All data represent mean ± SEM. Statistical analysis was 
performed on SPSS 20 (Statistical Package for Social 
Sciences, USA). Significance was estimated by the 
Kruskal–Wallis ANOVA followed by a post hoc test for 
distribution-free multiple comparisons (Bonferroni). 
Correlation between IGF-1 and weight was analyzed by 
Spearman test. Differences were considered significant at 
a level of p < 0.05.
Results
IGF‑1 circulating levels, body and liver weight
According to previous series [26, 31] 28 ± 6 weeks old Hz 
mice showed a significant decrease of circulating levels 
of IGF-1 as compared to CO. The exogenous administra-
tion of low doses of IGF-1 normalized IGF-1 serum levels 
in Hz +  IGF-1. Thus, the usefulness of the substitutive 
IGF-1 therapy at low doses was confirmed (see Fig. 1a).
As an anabolic hormone, IGF-1 deficiency induced 
body weight loss in untreated Hz mice as compared to 
controls.
Interestingly, IGF-1 treatment for only 10  days was 
able to restore the bodyweight (CO: 39.76 ±  2.45  g vs. 
Hz 33.59 ± 1.06 g, p < 0.01; Hz + IGF-1: 39.52 ± 1.48 g 
vs. Hz p  <  0.01). Absolute liver weight was signifi-
cantly decreased in Hz mice as compared to CO (Hz: 
1.63 ± 0.09 g vs. CO: 1.92 ± 0.16 g, p < 0.05), while differ-
ences between CO and Hz + IGF-1 mice were not found 
(Hz + IGF-1: 1.93 ± 0.19 g, p = ns).
Serum and liver analysis
Table  1 summarizes serum glucose, triglycerides and 
cholesterol values and hepatic levels of MDA, as a marker 
of oxidative damage in the three experimental groups. 
Untreated Hz mice showed a significant increase in all 
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these parameters. IGF-1 replacement therapy had the 
property to reduce, although not to completely abolish, 
the increases in glucose, triglycerides and cholesterol. 
Furthermore, it was able to diminish hepatic MDA to 
similar levels to those found in controls.
Liver gene expression studies
Microarray technique revealed several genes (Table  2) 
either hypo- or hyper-expressed in Hz as compared to 
CO mice (fold change over ±1.5), as well as Hz + IGF-1 











































































Fig. 1 IGF‑1 serum levels. IGF‑1 and IGFBPs liver gene expression. a IGF‑1 circulating levels at the end of the treatment determined in the three 
experimental groups. b Liver expression of igf-1, b igfbp1 and, d igfbp3 genes in the three experimental groups determined by RT‑qPCR and 
expressed as relative values compared to controls (fold change). **p < 0.01,*p < 0.05 vs. CO; &&p < 0.01, &p < 0.05 vs. Hz
Table 1 Serum and liver parameters for the three experimental groups
Control group, WT mice; Hz group including untreated mice with partial IGF-1 deficiency; Hz + IGF-1 group: Hz mice treated with low doses of IGF-1 during 10 days
** p < 0.01, * p < 0.05 vs. Controls; &  p < 0.05 vs. Hz group
Controls Untreated IGF‑1 deficient mice Treated IGF‑1 
deficient mice
Glucose (mg/dL) 83.07 ± 5.62 123.91 ± 11.27** 93.59 ± 3.95&
Triglycerides (mg/dL) 235.70 ± 11.50 291.01 ± 21.50* 254.11 ± 12.20&
Cholesterol (mg/dL) 221.76 ± 8.27 271.43 ± 12.76* 235.28 ± 4.86&
MDA (UM/mg protein/mL) 0.12 ± 0.02 0.16 ± 0.02* 0.07 ± 0.004&
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IGF‑1 and main IGFBPs gene expression
Among the genes with an altered expression, we firstly 
focused on those closely related to the physiology of 
IGF-1 (Table  2). Real time quantitative PCR was per-
formed to confirm changes over ±1.5-fold variance, such 
as IGF-1 and IGFBP-1 and IGFBP-3 (Fig. 1b–d).
Statistical differences were confirmed by RT-qPCR 
for igf-1, igfbp1 and igfbp3 genes. In the Hz group, igf-
1 expression was found significantly reduced and, unex-
pectedly, IGF-1 replacement therapy increased hepatic 
igf-1 expression (Fig. 1b).
On the other hand, igfbp1 and igfbp3 expressions were 
found significantly reduced in untreated Hz animals and 
substitutive IGF-1 treatment did not induce any change 
on the expression of these two genes (Fig. 1c, d).
Expression of genes involved in glucose metabolism
The expression of genes involved in glucose metabolism 
was analyzed by microarray analysis. RT-q PCR was 
performed to confirm changes over  ±1.5 fold change 
(Table  3). Gene expression of g6pc (glucose-6-phos-
phatase, catalytic), pck1 (phosphoenolpyruvate car-
boxykinase 1, cytosolic), pdk4 (pyruvatedehydrogenase 
kinase, isoenzyme 4) and acly (ATP citratelyase) was 
found significantly diminished in Hz as compared to CO. 
Interestingly, low doses of IGF-1 were able to normalize 
all these values to those found in the CO group (Fig. 2).
Lipid metabolism gene expression
A significant decrease in expression of genes involved in 
lipid catabolism, such as acaa 1b (acetyl-CoA acyltrans-
ferase 1), acat 1 (acetyl CoA acetyltransferase) was found 
(Fig. 3a). Hepatic expression of the acaa 1b gen was nor-
malized in animals deficient in IGF-1 when receiving 
replacement therapy for 10  days. No significant differ-
ences between CO and Hz + IGF-1 were found in acat1 
expression.
Likewise, partial deficiency of IGF-1 was associated 
with liver hypoexpression of genes that code for enzymes 
involved in cholesterol synthesis: hmgcs1 (3-hydroxy-
3-methylglutaryl-CoA synthase1), hmgcr (3-hydroxy-
3-methylglutaryl-CoA reductase): see Fig.  3b; and those 
encoding low-density lipoprotein receptor related pro-
teins, pcsk9 (proprotein convertase subtilisin/Kesin type 
9) and lpr1 (low density lipoprotein receptor-related pro-
tein 1). The expressions of all these genes were normal-
ized by IGF-1 replacement therapy (Figs. 3b, 4a).
Fatty acid transport and triglyceride catabolism
It was found that the partial IGF-1 deficiency resulted in 
the genetic downregulation of fabp1 (fatty acid binding 
protein 1, liver) and an overexpression of fabp5 (fatty acid 
binding protein 5, epidermal). RT-qPCR confirmed these 
findings and showed that fabp5 was sensitive to replace-
ment therapy with IGF-1 (Fig. 4b).
Furthermore, animals with partial IGF-1 deficiency 
showed an overexpression of the lipoprotein lipase gene 
(lpl) confirmed by RT-qPCR (Fig.  4c). No differences in 
the expression of genes encoding proteins involved in the 
regulation of fatty acid biosynthesis were found (Table 4).
Discussion
In the last decades many authors have tried to eluci-
date the involvement of different factors in the estab-
lishment of MetS including impaired glucose and lipid 
metabolism, lipotoxicity, steatosis, oxidative stress, obe-
sity, interrupted neuro-hormonal regulation and altered 
intracellular Ca2+ trafficking [10–14].
Table 2 Liver expression of genes related to IGF-1
Control group, WT mice; Hz group including untreated mice with partial IGF-1 deficiency; Hz + IGF-1 group: Hz mice treated with low doses of IGF-1 during 10 days. 
Underlined values correspond to those with a fold-change >1.5, considered as a significant variation in the gene expression
Protein Gene Hz vs. WT  
(fold change)
p value Hz + IGF vs. Hz  
(fold change)
p value
Insulin‑like growth factor 1 (Igf1) −2.48 0.0017 1.64 0.002
Insulin‑like growth factor 2 (Igf2) −1.35 0.14 1.48 0.16
Insulin‑like growth factor binding protein 1 (Igfbp1) −4.53 0.0001 −2.2 0.0012
Insulin‑like growth factor binding protein 2 (Igfbp2) −1.18 0.015 −1.02 0.37
Insulin‑like growth factor binding protein 3 (Igfbp3) −1.78 0.012 1.33 0.011
Insulin‑like growth factor binding protein 4 (Igfbp4) 1.13 0.33 1.35 0.29
Insulin‑like growth factor binding protein 5 (Igfbp5) −1.37 0.10 1.37 0.17
Insulin‑like growth factor binding protein 6 (Igfbp6) −1.10 0.31 1.19 0.12
Albumin (Alb) −1.06 0.12 −1.01 0.14
Parvalbumin (Pvalb) −1.04 0.11 −1.10 0.13
Lactalbumin, alpha (Lalba) −1.10 0.14 1.04 0.12
D site albumin promoter binding protein (Dbp) 2.33 0.05 −1.16 0.19
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Lately, increasing evidence points to a central role 
of IGF-1 in the pathological pathways leading to the 
establishment of MetS [32]. Several recent studies have 
attempted to correlate low IGF-1 serum levels with MetS 
[33, 34]. In this context, the present study was focused on 
determining how the IGF-1 deficiency “per se” could con-
tribute to the establishment of MetS.
With this objective, it was used a recently characterized 
experimental model of haploinsufficiency in which mice 
hypoexpressing the igf1 gene (igf+/−, Hz = heterozygous) 
show low circulating IGF-1 levels [26, 31].
The IGF-1 deficiency correlated with a significant 
reduction in body weight [26] and the replacement ther-
apy was able to restore both IGF-1 serum levels and body 
weight in accordance with previous results [31].
Data in this paper show that the mere IGF-1 deficiency 
in adult mice is responsible for altering the hepatic expres-
sion of genes involved in glucose and lipid metabolism 
leading to hypertriglyceridemia, hypercholesterolemia and 
hyperglycemia (Table  1). The IGF-1 therapy was able to 
revert all these parameters with only 10 days of treatment.
The adult mice used in this work lived within very con-
trolled conditions (diet, drink, temperature) avoiding all 
exogenous insults. Consequently, all of the findings in 
this study are due to the mere IGF-1 deficiency.
One of the most noticeable results in this paper is that 
the mere IGF-1 deficiency reduced the liver expression 
of genes coding for phosphoenolpyruvate carboxykin-
ase (PEPCK) and glucose-6-phosphatase (G6Pase), key 
enzymes involved in gluconeogenesis and both restored 
to normal values by IGF-1 therapy.
The net glucose release is the result of two simultane-
ous ongoing pathways that are tightly regulated. The 
liver produces glucose by breaking down glycogen (gly-
cogenolysis) and by “de novo” synthesis of glucose (glu-
coneogenesis) from non-carbohydrate precursors such as 
lactate, amino acids and glycerol [35].
The rate of gluconeogenesis is mainly controlled by 
the activities of unidirectional enzymes such as PEPCK 
and G6Pase [36]. Pck1 is involved in the expression of the 
enzyme that catalyzes one of the rate limiting steps of 
gluconeogenesis, the conversion of oxaloacetate to phos-
phoenolpyruvate (PEP), while G6Pase catalyzes the final 
step of gluconeogenesis, the production of free glucose 
from glucose-6-phosphate (G6P). Until now, it is well 
known that the genes of these gluconeogenic enzymes 
are controlled at the transcriptional level by hormones, 
mainly insulin, glucagon and glucocorticoids [36].
Interestingly, it is well recognized that insulin decreases 
the expression of g6pc and pck1. Results in this paper 
Table 3 Liver expression of genes related to glucose metabolism
Control group, WT mice; Hz group including untreated mice with partial IGF-1 deficiency; Hz + IGF-1 group: Hz mice treated with low doses of IGF-1 during 10 days. 
Underlined values correspond to those with a fold-change >1.5, considered as a significant variation in the gene expression
Protein Gene Hz vs. WT  
(fold change)
p value Hz + IGF vs. Hz  
(fold change)
p value
Fructosebisphosphatase 1 (Fbp1) 1.40 0.02 −1.49 0.01
Fructosebisphosphatase 2 (Fbp2) 1.64 0.017 1.06 0.42
Glucose‑6‑phosphatase, catalytic (G6pc) −1.92 0.001 −1.71 0.0059
Glucose 6 phosphatase, catalytic, 3 (G6pc3) −1.01 0.56 1.31 0.017
Phosphoenolpyruvatecarboxykinase 1, cytosolic (Pck1) −2.42 0.001 1.35 0.08
Phosphoenolpyruvatecarboxykinase 2 (mitochondrial) (Pck2) −1.14 0.45 1.10 0.40
Pyruvate carboxylase (Pcx) −1.01 0.18 1.05 0.09
Pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1) −1.46 0.0035 1.23 0.19
Pyruvate dehydrogenase kinase, isoenzyme 2 (Pdk2) −1.17 0.03 1.33 0.035
Pyruvate dehydrogenase kinase, isoenzyme 3 (Pdk3) 1.23 0.42 −1.01 0.94
Pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4) −1.83 0.03 −1.01 0.85
Pyruvate dehyrogenase phosphatase catalytic subunit 2 (Pdp2) −1.08 0.09 1.21 0.04
ATP citratelyase (Acly) −1.67 0.0007 1.60 0.006
Aconitase 1 (Aco1) −1.30 0.38 1.17 0.23
Aconitase 2, mitochondrial (Aco2) −1.18 0.013 1.16 0.85
Dihydrolipoamide S‑acetyltransferase (Dlat) 1.03 0.13 −1.15 0.19
Dihydrolipoamidedehydrogenase (Dld) −1.02 0.03 1.11 0.73
Dihydrolipoamide S‑succinyltransferase (Dlst) 1.14 0.40 1.41 0.01
Isocitratedehydrogenase 1 (NADP+), soluble (Idh1) 1.07 0.04 −1.38 0.07
Isocitratedehydrogenase 2 (NADP+), mitochondrial (Idh2) −1.10 0.45 1.01 0.25
Isocitratedehydrogenase 3 (NAD+) alpha (Idh3a) −1.21 0.09 1.06 0.01
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demonstrate that IGF-1 induces the opposite effects since 
the IGF-1 deficit reduces the expression of g6pc and pck1. 
Thus, these activities of IGF-1 are not “insulin like” but 
rather antagonistic. These findings reinforce the role 
of IGF-1 in glucose homeostasis, recently suggested by 
many authors [5, 37–40].
It is well known that insulin and IGF-1 share structural 
homology and interact with the same membrane recep-
tors, albeit with different affinities. Insulin and IGF-1 
exert complementary biological actions, which are path-
ologically important when one of the hormone levels 
drops significantly [14].
In this sense, a different result within this paper, that 
deserves an especial mention, is the hypoexpression of pdk4 
in IGF-1 deficient mice, which IGF-1 replacement therapy 
was able to revert. This gene (pdk4) encodes pyruvate-dehy-
drogenase complex (PDK). PDK is an emerging target for 
the treatment of MetS. To maintain a steady-state concen-
tration of adenosine triphosphate during the feed-fast cycle, 
cells require efficient utilization of fatty acid and glucose, 
which is controlled by PDK [41]. Particularly the pdk4 gene 
encodes PDK that converts pyruvate, CoA and oxidized nic-
otinamide adenine dinucleotide (NAD+) into acetyl-CoA, 
the reduced form of nicotinamide adenine dinucleotide 
(NADH) and carbon dioxide. The activity of PDK is up- 
and downregulated by pyruvate dehydrogenase kinase and 
pyruvate dehydrogenase phosphatase, respectively. In addi-
tion, pyruvate is a key intermediate of glucose oxidation and 
an important precursor for the synthesis of glucose, glyc-





































































Fig. 2 Liver expression of genes involved on gluconeogenesis and glycogenolysis. Expression of g6pc (Glucose‑6‑phosphatase), pck1 (Phospho‑
enolpyruvate‑carboxylase 1), pdk4 (Pyruvate dehydrogenase kinase isoenzyme 4) and acly (ATP‑citrate lyase) genes determined by RT‑qPCR and 
expressed as relative values compared to controls (fold change). *p < 0.05 vs. CO;  &p< 0.05 vs. Hz
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As aforementioned, untreated Hz mice 28 ±  6  weeks 
old showed hyperglycemia as compared to controls and 
Hz + IGF-1. Interestingly a similar finding was reported 
in aging rats, which showed low circulating levels of 
IGF-1 [7]. Unfortunately, in the present work insulin 
measurements and HOMA assessments are absent due 
to the little volume of blood that can be extracted from 
mice.
Results in this paper are in accordance with observa-
tions from other authors. It has been recently reported 
that a postprandial hyperglycemia in patients with Laron 
Syndrome was due to chronic IGF-1 deficiency and was 
reversed by IGF-1 replacement therapy [40].
Laron and Weinberger reported in 2004 two cases 
of untreated patients with congenital IGF-1 deficiency 
(Laron Syndrome), who developed T2D when they 
reached 39 and 41  years of age [42]. In our experience 
(data not published yet), this clinical development in 
never-treated patients with Laron Syndrome is quite 
frequent when other factors (especially diet) converge. 
Another recent study found that sensitivity to T2D is 
gender dependent in mice with impaired IGF-1 actions, 
showing that without high fat diet feeding males tend to 
develop glucose intolerance with age along with insulin 















































































Fig. 3 Liver expression of genes implicated in lipid metabolism. a Gene expression of acaa 1b (Acetyl‑CoA acyltransferase 1B) and acat1 (Acetyl‑
CoA acetyltransferase 1), implicated in lipid catabolism; b liver expression of the genes related to lipid synthesis hmgcs1 (3‑Hidroxi‑3‑metilglutaril‑
CoA ‑sinthetase 1) and hmgrc (3‑hydroxy‑3‑methylglutaryl‑CoA reductase). All determined by RT‑qPCR and expressed as relative values compared 
to controls (fold change). ***p < 0.001, **p < 0.01, *p < 0.05 vs. CO; &&p< 0.01, &p < 0.05 vs. Hz
























































































Fig. 4 Liver genes implicated in lipid transport. a Genes related to low density lipoprotein receptor‑related protein synthesis: pcsk9 (Proprotein 
convertase subtilisin/kexin type 9) and lrp1 (Low density lipoprotein receptor‑related protein 1); b expression of the genes related to fatty acid trans‑
port fabp1 (Fatty acid binding protein 1) and fabp5 (Fatty acid binding protein 5); and c the gene related to triacylglycerol catabolism lpl (Lipopro‑
tein lipase). All determined by RT‑qPCR and expressed as relative values compared to controls (fold change). **p < 0.01, *p < 0.05 vs. CO; &&p <0.01, 
&p < 0.05 vs. Hz
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In addition, untreated Hz mice exhibit a significant 
reduction in the hepatic expression of acly, which was 
normalized by IGF-1 replacement therapy. Acly encodes 
ATP-citrate lyase, one of the two cytosolic enzymes that 
synthesize acetyl-CoA. Because acetyl-CoA is an essen-
tial building block for cholesterol and triglycerides, acly 
has been considered a therapeutic target for hyperlipi-
demias and obesity [44]. In the present work untreated 
Hz mice with a tightly controlled diet and 28 ± 6 weeks 
old, showed increased circulating levels both triglycer-
ides and cholesterol (Table 1), which the IGF-1 replace-
ment therapy improved.
Accordingly, results in this paper describe a decreased 
expression of genes encoding several enzymes involved 
in lipid metabolism: acaa 1b (acetyl-CoA acyltransferase 
1B), acat 1 (acetyl-CoA acetyltransferase 1) (Fig.  3a). 
Acaa 1b encodes an enzyme operative in the beta-oxida-
tion system of the peroxisomes. Acetyl-CoA acyltrans-
ferase 1 is involved in the regulation of genes encoding 
cholesterol biosynthesis enzymes in the liver, suggesting 
that the peroxisome could be a promising candidate for 
the correction of cholesterol imbalance in dyslipidemia 
[45].
These data suggest a relevant function for IGF-1 in 
β-oxidation and cholesterol synthesis. On the other 
hand, two key enzymes for cholesterol biosynthesis were 
found reduced in the untreated Hz group and reverted 
by IGF-1 therapy: hmgcr (3-hydroxy-3-methylglutaryl-
Co-A reductase—HMG-CoA reductase), and hmgcs1 
(3-hydroxy-3-methylglutaryl-CoA synthase 1—HMG-
CoA synthase 1) (Fig. 3b).
The reaction catalyzed by HMG-CoA reductase is rate-
limiting for cholesterol synthesis. This enzyme is highly 
regulated and is a target for pharmaceutical interven-
tion to control hypercholesterolemia [46]. HMG-CoA 
reductase catalyzes the production of mevalonate from 
HMG-CoA. The carboxyl group of hydroxymethylgluta-
rate linked by an ester bond to the thiol of Co-A is first 
reduced to an aldehyde and then to an alcohol. NADPH 
serves as a reductant in the 2-step reaction [47]. Meval-
dehyde is thought to be an active site intermediate, fol-
lowing the first reduction and the release of CoA [47–49].
Table 4 Liver expression of genes related to lipid metabolism
Control group, WT mice; Hz group including untreated mice with partial IGF-1 deficiency; Hz + IGF-1 group: Hz mice treated with low doses of IGF-1 during 10 days. 
Underlined values correspond to those with a fold-change >1.5, considered as a significant variation in the gene expression
Protein Gene Hz vs. WT  
(fold change)
p value Hz + IGF vs. Hz  
(fold change)
p value
Acetyl‑Coenzyme A acyltransferase 1B (Acaa1b) −4.04 0.002 2.28 0.00012
Acetyl‑Coenzyme A acetyltransferase 1 (Acat1) −1.62 0.00006 1.21 0.017
Acetyl‑Coenzyme A acetyltransferase 2 (Acat2) −1.50 0.04 1.34 0.02
Acyl‑Coenzyme A oxidase 1, palmitoyl (Acox1) −1.70 0.004 1.14 0.13
Acyl‑CoA synthetase long‑chain family member 1 (Acsl1) −2.20 0.0001 1.85 0.011
Acyl‑CoA synthetase long‑chain family member 3 (Acsl3) −1.96 0.018 −1.06 0.19
Acyl‑CoA synthetase medium‑chain family m2 (Acsm2) −1.09 0.57 1.50 0.002
Acyl‑CoA thioesterase 9 (Acot9) 1.77 0.008 −1.70 0.006
Cytochrome b5 reductase 3 (Cyb5r3) −1.52 0.04 1.46 0.03
Phenylalkylamine Ca2+ antagonist (emopamil) binding 
protein
(Ebp) 1.49 0.13 −1.16 0.21
3‑hydroxy‑3‑methylglutaryl‑Coenzyme A reductase (Hmgcr) −2.77 0.0018 1.37 0.003
3‑hydroxy‑3‑methylglutaryl‑Coenzyme A synthase1 (Hmgcs1) −1.49 0.019 1.45 0.04
Isopentenyl‑diphosphate delta isomerase (Idi1) −1.49 0.013 1.38 0.02
Mevalonate (diphospho) decarboxylase (Mvd) −2.13 0.002 1.69 0.01
ATP‑binding cassette, sub‑family G (WHITE), member 1 (Abcg1) 1.83 0.004 −1.66 0.05
Aldo–keto reductase family 1, member D1 (Akr1d1) −2.36 0.0002 1.21 0.018
Cytochrome P450, family 46, subfamily a, polypeptide 1 (Cyp46a1) −1.77 0.004 1.01 0.17
Cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1) −2.76 0.0002 1.54 0.0013
Very low density lipoprotein receptor (Vldlr) −3.12 0.0002 1.20 0.02
Low density lipoprotein receptor‑related protein 1 (Lrp1) −1.49 0.0004 1.13 0.58
Proprotein convertase subtilisin/kexin type 9 (Pcsk9) −1.59 0.03 1.45 0.03
Fatty acid binding protein 1, liver (Fabp1) −1.53 0.03 1.50 0.007
Fatty acid binding protein 5, epidermal (Fabp5) 5.06 0.0002 −2.27 0.006
Lipoprotein lipase (Lpl) 2.02 0.0012 −2.50 0.002
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The enzyme HMG-CoA synthase catalyzes the con-
densation of an acetoacetyl-CoA and an acetyl-CoA to 
form HMG-CoA plus free CoA. HMG-CoA synthase 
activity is found both in the cytosol and in the mito-
chondria. The HMG-CoA produced by the cytosolic 
HMG-CoA synthase is converted to mevalonate by the 
action of HMG-CoA reductase. This reaction starts the 
isoprenoid pathway, whose main end-product is choles-
terol [50].
Although results in this study show a diminished capa-
bility for IGF-1 deficient mice in cholesterol synthesis, as 
hmgcr, hmgcs1 and acly (enzymes involved in cholesterol 
synthesis) are downregulated, augmented serum choles-
terol levels were found. This fact could be explained by 
the downregulation of lrp1 (LDL-receptor related protein 
1) and pcsk9 (proprotein convertase subtilisin/Kesin type 
9) both LDL-receptor related proteins, which could be 
impairing reverse cholesterol transport from the diet.
Moreover, results regarding lipid metabolism are in 
accordance with previous studies from this group under-
taken in murine aging model, which sustain that IGF-1 
and cholesterol have an inverse correlation [7] and 
are also associated with a mitochondrial dysfunction 
[51], reversible with IGF-1 treatment. Contrarily, stud-
ies undertaken in adult humans [52] disagree with such 
finding, suggesting that IGF-1 does not have an impor-
tant role in cholesterol metabolism, but, however, agreed 
when they found that IGF-1 levels and triglycerides were 
inversely correlated [52].
On the other hand, a study undertaken in adult indi-
viduals showed that IGF-1 levels were positively related 
with HDL concentrations [52]. Also, in animal models it 
has been observed that IGF-1 gene expression is higher 
in adipose tissue compared to other organs [53]. This is in 
accordance with the fact that IGF-1 could have a lipolytic 
paracrine effect on adipocytes [54].
IGF-1 circulating levels decline with age. Previously it 
has been reported that aging rats showed low IGF-1 cir-
culating levels associated to hyperlipidemia (cholesterol 
and triglycerides), hyperglycemia with insulin resist-
ance [7], as well as an increase of peroxidative liver dam-
age and mitochondrial dysfunction [51]. The exogenous 
administration of IGF-1, at low doses (similar to those 
used in the present work), restored IGF-1 serum levels 
reducing dyslipidemia and insulin resistance, oxidative 
liver damage and mitochondrial dysfunction [7, 51].
Likewise results in this paper show an increase in MDA 
homogenate levels, indicative of oxidative damage in the 
liver of untreated mice with partial IGF-1 deficiency as 
compared to controls. In addition, IGF-1 therapy induced 
a reduction of MDA levels even under control values, 
suggesting an antioxidant activity of IGF-1 according to 
previously reported results [8].
One recent large-scale community based Framingham 
Heart Study suggested that lower IGF-1 levels are associ-
ated with insulin resistance and MetS [55]. All of these 
data are in accordance with the observations of reduced 
IGF-1 levels in individuals with MetS and its various 
components [14].
The primary condition of IGF-1 deficiency in humans is 
Laron Syndrome, characterized by low body weight and 
stature, similar to the one found in mice. However, more 
recently, IGF-1 deficiency has been associated with an 
increased prevalence of obesity. A general finding is that 
obese patients that fulfill the criteria for MetS presenting 
low IGF-1 plasma levels, tend to develop a worse cardio-
vascular disease outcome than those with mid-normal 
to high-normal IGF-1 level [32]. Findings in this work 
support this idea as metabolic deregulation has been 
suggested. Although mice with partial IGF-1 deficiency 
exhibit retarded body weight gain, they have not been 
exposed to a high fat diet or any other external insult, as 
they were kept within strictly controlled conditions, thus 
being IGF-1 deficiency the only feasible component caus-
ing metabolic imbalance. Such deregulation found could 
render these animals to the deleterious effects of obesity 
if fed with a high fat diet, presumably leading to meta-
bolic syndrome.
In fact, circulating IGF-1 levels are reported to be 
inversely correlated with the risk of cardiovascular dis-
eases [14]. For example, elderly patients with low circu-
lating IGF-1 levels are at a much higher risk of ischemic 
stroke and congestive heart failure [56].
Visceral adipose tissue is inversely correlated with 
circulating IGF-1 levels [33]. In this sense, it was also 
reported that obesity (always visceral obesity) found in 
patients with Laron Syndrome is not due to either exces-
sive nutritional intake nor hypometabolism [57].
Conclusions
In conclusion, our present data, supported by litera-
ture evidence, indicates that IGF-1 deficiency is deeply 
involved in the establishment of MetS while not a defini-
tive factor in its development. Findings in this paper offer 
a plausible explanation for some of the mechanisms link-
ing IGF-1 deficiency to the establishment of MetS and 
suggest this condition to be a novel candidate for IGF-1 
replacement therapy.
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